ACM
KZIA

ACT Capital Management’s Kazia Therapeutics KZIA Stock Holding History

ACT Capital Management’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500
Closed -$247K – 121
2021
Q2 		$247K Buy
+500
New +$263K 0.13% 83

Other funds holding KZIA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

ACT Capital Management's KZIA Position: Q3 2021 in Review

ACT Capital Management sold out of Kazia Therapeutics (KZIA) in Q3 2021, closing a stake of 500 shares — an estimated $247K sold.

ACT Capital Management first reported a position in KZIA in Q2 2021 and held it in 1 quarter. The position peaked at $247K in Q2 2021. 15 funds tracked by Wall St. Rank hold KZIA as of Q3 2021.

  • ACT Capital Management reported no remaining Kazia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • ACT Capital Management sold 500 Kazia Therapeutics shares in Q3 2021, an estimated $247K.
  • ACT Capital Management first reported a position in Kazia Therapeutics in Q2 2021 and held it in 1 quarter.
  • ACT Capital Management's Kazia Therapeutics position peaked at $247K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.